Clinical Trials Browser

Phase 1/2 × sapanisertib × Clear all

NCT06811116 2026-03-18

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02244463 2024-01-12

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1/2 Completed

46 enrolled 18 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02575339 2022-07-26

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Phase 1/2 Terminated

11 enrolled 15 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02514824 2020-12-29

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 1/2 Completed

9 enrolled 10 charts

Carcinoma, Merkel Cell

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma